Athersys Stock Forecast, Price & News

Athersys (NASDAQ:ATHX) Frequently Asked Questions

Is Athersys a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Athersys stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATHX, but not buy additional shares or sell existing shares.
View analyst ratings for Athersys or view top-rated stocks.

How has Athersys' stock price been impacted by COVID-19 (Coronavirus)?

Athersys' stock was trading at $1.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATHX stock has decreased by 14.1% and is now trading at $1.10.
View which stocks have been most impacted by COVID-19.

Are investors shorting Athersys?

Athersys saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 16,350,000 shares, an increase of 25.8% from the October 14th total of 13,000,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the days-to-cover ratio is currently 13.2 days. Currently, 7.9% of the company's shares are sold short.
View Athersys' Short Interest.

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Athersys.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) posted its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.01. During the same period last year, the firm earned ($0.11) earnings per share.
View Athersys' earnings history.

What price target have analysts set for ATHX?

1 Wall Street analysts have issued 1 year price targets for Athersys' shares. Their forecasts range from $1.25 to $1.25. On average, they anticipate Athersys' stock price to reach $1.25 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price.
View analysts' price targets for Athersys or view top-rated stocks among Wall Street analysts.

Who are Athersys' key executives?

Athersys' management team includes the following people:

• William B. J. Lehmann, President, Chief Executive & Operating Officer (LinkedIn Profile)
• Ivor MacLeod, Chief Financial & Accounting Officer (LinkedIn Profile)
• John J. Harrington, Director, Chief Scientific Officer & Executive VP (LinkedIn Profile)
• Rakesh Ramachandran, Head-Information Technology & Communications
• Eric Jenkins, Senior Director-Medical & Head-Clinical Operations

What is Gil Van Bokkelen's approval rating as Athersys' CEO?

2 employees have rated Athersys CEO Gil Van Bokkelen on Glassdoor.com. Gil Van Bokkelen has an approval rating of 100% among Athersys' employees. This puts Gil Van Bokkelen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Athersys' key competitors?

Some companies that are related to Athersys include Design Therapeutics (DSGN), Amphastar Pharmaceuticals (AMPH), CannTrust (CNTTF), Edgewise Therapeutics (EWTX), Tango Therapeutics (TNGX), Rani Therapeutics (RANI), Kiniksa Pharmaceuticals (KNSA), Repare Therapeutics (RPTX), BELLUS Health (BLUSF), Zealand Pharma A/S (ZEAL), Seres Therapeutics (MCRB), RAPT Therapeutics (RAPT), Vanda Pharmaceuticals (VNDA), IDEAYA Biosciences (IDYA) and Syndax Pharmaceuticals (SNDX).
View all of ATHX's competitors.

What other stocks do shareholders of Athersys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA).

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Who are Athersys' major shareholders?

Athersys' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.41%), Geode Capital Management LLC (1.63%), Jacob Asset Management of New York LLC (0.36%), Bank of New York Mellon Corp (0.30%), Millennium Management LLC (0.26%) and UBS Group AG (0.21%). Company insiders that own Athersys stock include Ismail Kola, Ivor Macleod, John J Harrington, John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr.
View institutional ownership trends for Athersys.

Which major investors are selling Athersys stock?

ATHX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Goldman Sachs Group Inc., Livingston Group Asset Management CO operating as Southport Capital Management, NEXT Financial Group Inc, Morgan Stanley, UBS Group AG, Cedar Brook Financial Partners LLC, and Jane Street Group LLC. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell, and William Lehmann Jr.
View insider buying and selling activity for Athersys or view top insider-selling stocks.

Which major investors are buying Athersys stock?

ATHX stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Geode Capital Management LLC, BlackRock Inc., Citadel Advisors LLC, Jacob Asset Management of New York LLC, SG Americas Securities LLC, Metropolitan Life Insurance Co NY, and Cerity Partners LLC. Company insiders that have bought Athersys stock in the last two years include Ismail Kola, Ivor Macleod, and Kenneth H Traub.
View insider buying and selling activity for Athersys or or view top insider-buying stocks.

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $1.10.

How much money does Athersys make?

Athersys has a market capitalization of $258.76 million and generates $1.44 million in revenue each year. The biopharmaceutical company earns $-78.76 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Athersys have?

Athersys employs 97 workers across the globe.

When was Athersys founded?

Athersys was founded in 1995.

What is Athersys' official website?

The official website for Athersys is www.athersys.com.

Where are Athersys' headquarters?

Athersys is headquartered at 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at [email protected], or via fax at 216-361-9495.